Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The schizophrenia market size was $9.0 billion in 2021 and is expected to achieve a CAGR of more than 3% during 2021-2031. Schizophrenia is characterized by several symptom domains including positive symptoms (such as hallucinations, delusions, and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including impaired attention, memory, and executive functions).

Schizophrenia Market Size

To gain more information on the schizophrenia market forecast, download a free report sample

The schizophrenia market research report provides an overview of the risk factors, comorbidities, and global and historical trends for schizophrenia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for total prevalent cases and diagnosed prevalent cases of schizophrenia.

  Market Size (2021)  $9.0 billion
  CAGR (2021 – 2031)  >3%
Key Age Segments 13-17 Years, 18-19 Years, 20-29 Years, 30-39 Years, 40-49 Years, 50-59 Years, 60-69 Years, 70-79 Years, and Above 80 years
Key Sex Segments Men and Women
  Leading Players Acadia Pharmaceuticals, BioXcel Therapeutics, Boehringer Ingelheim, Eli Lilly, Gedeon Richter, Intra-Cellular Therapies, Johnson & Johnson, Karuna Therapeutics, Lundbeck, Luye Pharma, MedinCell, Minerva Neurosciences, Neurocrine Biosciences, Novartis, Otsuka, Reviva Pharmaceuticals, Sunovion Pharmaceuticals, and Teva

Schizophrenia Market Drivers

The major drivers of growth in the schizophrenia market include the launch of 11 new pipeline products which will have a higher annual cost of therapy (ACOT). The potential for novel pharmacological therapies specifically indicated for cognitive impairment associated with schizophrenia (CIAS) and the negative symptoms of schizophrenia could provide new options for patients. Moreover, the prospect of novel adjunctive therapies will be welcomed for patients who have a partial response to marketed antipsychotics.

Schizophrenia Market Segmentation by Age

The schizophrenia market can be segmented based on age into 13-17 years, 18-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and above 80 years.

In 2021, for the 7MM combined, adults ages 50–59 years contributed the highest proportion of the 12-month diagnosed prevalent cases of schizophrenia followed by the age group 40–49 years and ages 30-39 years.

Schizophrenia Market Analysis by Age

Schizophrenia Market Analysis by Age

For more age segment insights into the schizophrenia market, download a free report sample

Schizophrenia Market Segmentation by Sex

The schizophrenia market can be segmented based on sex into men and women.

In the 7MM combined, the number of diagnosed prevalent cases of schizophrenia was higher in women than in men in 2021. The difference in sex distribution is most pronounced in the US, where most diagnosed prevalent cases of schizophrenia occur in women.

Schizophrenia Market Analysis by Sex

Schizophrenia Market Analysis by Sex

For more sex segment insights into the schizophrenia market, download a free report sample

Competitive Landscape

Some of the leading players in the schizophrenia market are Acadia Pharmaceuticals, BioXcel Therapeutics, Boehringer Ingelheim, Eli Lilly, Gedeon Richter, Intra-Cellular Therapies, Johnson & Johnson, Karuna Therapeutics, Lundbeck, Luye Pharma, MedinCell, Minerva Neurosciences, Neurocrine Biosciences, Novartis, Otsuka, Reviva Pharmaceuticals, Sunovion Pharmaceuticals, and Teva.

Schizophrenia Market Report Overview

  Market Size (2021)  $9.0 billion
  CAGR (2021 – 2031)  >3%
Key Age Segments 13-17 Years, 18-19 Years, 20-29 Years, 30-39 Years, 40-49 Years, 50-59 Years, 60-69 Years, 70-79 Years, and Above 80 years
Key Sex Segments Men and Women
  Leading Players Acadia Pharmaceuticals, BioXcel Therapeutics, Boehringer Ingelheim, Eli Lilly, Gedeon Richter, Intra-Cellular Therapies, Johnson & Johnson, Karuna Therapeutics, Lundbeck, Luye Pharma, MedinCell, Minerva Neurosciences, Neurocrine Biosciences, Novartis, Otsuka, Reviva Pharmaceuticals, Sunovion Pharmaceuticals, and Teva

Scope 

  • Overview of schizophrenia, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized schizophrenia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the schizophrenia therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for schizophrenia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
  • Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Acadia Pharmaceuticals
BioXcel Therapeutics
Boehringer Ingelheim
Eli Lilly
Gedeon Richter
Intra-Cellular Therapies
Johnson & Johnson
Karuna Therapeutics
Lundbeck
Luye Pharma
MedinCell
Minerva Neurosciences
Neurocrine Biosciences
Novartis
Otsuka
Reviva Pharmaceuticals
Sunovion Pharmaceuticals
Teva

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Schizophrenia: Executive Summary

1.1 The schizophrenia market will grow to $13.0 billion

1.2 Key players will struggle to maintain their competitive position

1.3 While outlook in schizophrenia improves, opportunities remain to improve patient outcomes

1.4 The entry of adjunctive therapies will shape the schizophrenia market

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia

4.5 Epidemiological Forecast for Schizophrenia (2021–31)

4.5.1 12-Month total prevalent cases of schizophrenia

4.5.2 12-Month diagnosed prevalent cases of schizophrenia

4.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia

4.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis overview

5.2 Treatment overview

5.3 Other KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Development of therapies to target cognitive impairment associated with schizophrenia

7.3 Development of therapies to target negative symptoms

7.4 Development of therapies for treatment-resistant patients

7.5 Improved patient insight and adherence to treatment

8 R&D Strategies

8.1 Overview

8.1.1 Reformulations and innovative drug delivery systems

8.1.2 Novel MOAs

8.1.3 Development of adjunctive therapies

8.1.4 Digital therapeutics

8.2 Clinical trial design

8.2.1 Clinical endpoints

8.2.2 Patient Recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecasts

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs and Payers

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologists

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Schizophrenia: Key metrics in the 7MM

Table 2: Risk factors and comorbid conditions associated with schizophrenia

Table 3: Treatment Guidelines for Schizophrenia

Table 4: Schizophrenia market – global drivers and barriers, 2021–2031

Table 5: Key events impacting sales for schizophrenia in the US, 2021–2031

Table 6: Schizophrenia Market – Drivers and Barriers in the US, 2021–2031

Table 7: Key events impacting sales for schizophrenia in the 5EU, 2021–2031

Table 8: Schizophrenia market – drivers and barriers in the 5EU, 2021–2031

Table 9: Key Events Impacting Sales for Schizophrenia in Japan, 2021–2031

Table 10: Schizophrenia Market – Drivers and Barriers in Japan, 2021–2031

Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global sales forecast by country for schizophrenia in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in schizophrenia during the forecast period

Figure 3: Competitive assessment of novel oral atypical antipsychotic pipeline agents that GlobalData expects to be licensed for the treatment of schizophrenia during the forecast period

Figure 4: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna

Figure 5: 7MM, 12-month total prevalence (%) of schizophrenia, both sexes, ages ≥13 years, 2021

Figure 6: 7MM, 12-month diagnosed prevalence (%) of schizophrenia, men and women, ages ≥13 years, 2021

Figure 7: 7MM, sources used to forecast the 12-month total prevalent cases of schizophrenia

Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of schizophrenia

Figure 9: 7MM, 12-month total prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021

Figure 10: 7MM, 12-month diagnosed prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021

Figure 11: 7MM, 12-month diagnosed prevalent cases of schizophrenia by age, N, both sexes, 2021

Figure 12: 7MM, 12-month diagnosed prevalent cases of schizophrenia by sex, N, ages ≥13 years, 2021

Figure 13: Unmet needs and opportunities in schizophrenia

Figure 14: Overview of the development pipeline in schizophrenia

Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for schizophrenia in the 7MM during the forecast period

Figure 16: Competitive assessment of novel oral atypical antipsychotic pipeline drugs benchmarked against the SOC, Abilify

Figure 17: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna

Figure 18: Analysis of the company portfolio gap in schizophrenia during the forecast period

Figure 19: Global (7MM) sales forecast by country for schizophrenia in 2021 and 2031

Figure 20: Sales forecast by class for schizophrenia in the 7MM in 2021 and 2031

Figure 21: Sales forecast by class for schizophrenia in the US in 2021 and 2031

Figure 22: Sales forecast by class for schizophrenia in the 5EU in 2021 and 2031

Figure 23: Sales forecast by class for schizophrenia in Japan in 2021 and 2031

Frequently asked questions

Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 in real time.

  • Access a live Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.